“IOERT is becoming the gold standard in the successful treatment of cancer”, says Ernesto G. Lanzotti, Director of MD51 Germany GmbH, IntraOp Medical European distributor. “The clinical data showing the effectiveness of IOERT, compared to conventional treatment is very convincing. German hospitals are all looking to provide their patients the best cancer treatment possible—and that is IOERT. We are very proud to start cooperating with helios-kliniken.de because we understand the importance from both a treatment and medical science aspect and the potential they will be able to bring in terms of future treatments. With our existing German customers already operating in Germany at a level of excellence, we are sure IOERT will have a big increase already in the next few months”

Helios Berlin Buch in the city of Berlin is the reference site among most important treatment centers in Germany, very famous for its Breast Cancer unit and for the state of the art in Medical Technology.

“We are very excited to add Helios Group to growing list of world class cancer centers using the Mobetron. IOERT for breast cancer is becoming very prevalent throughout Europe.” said John Powers, President and CEO of IntraOp Medical. IntraOp’s Mobetron is a mobile, self-shielded, device that delivers radiation directly to the tumor site during cancer surgery protecting surrounding body structures from radiation. This procedure is called IORT. The Mobetron uses electron radiation, IOERT, which is the fastest, safest, most versatile, and precise way to deliver radiation therapy. The Mobetron delivers concentrated electron radiation directly to the exposed tumor bed to an exact depth during cancer surgery.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms or office settings and has been used to treat over 20 different cancer indications. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

IntraOp Medical’s European Patent EP 0 700 578 describes for the Federal Republic of Germany an electron linear accelerator treatment device, which is suitable for Intra-Operative Electron Beam Radiation Therapy (IOERT). This patent has been maintained with a slight revision to better clarify the device. The German text of the European Patent EP 0 700 578 may be obtained from the German Patent and Trademark Office Link.

“It is good to have this ruling validate the inventiveness of the Mobetron, which has provided the clinical community a totally new way to deliver IOERT. The Mobetron mobile IOERT technology has already enabled important clinical studies in early stage breast cancer, and clinical trials for pancreatic cancer and rectal cancer are being developed, These studies would not have been practical or even possible to implement without the Mobetron mobile IOERT development.” said Don Goer, Chief Scientist and founder of IntraOp. John Powers, IntraOp CEO further said “we will continue to aggressively defend our patents. This decision clearly helped reinforce the strength of our IP.”

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms or office settings and has been used to treat over 20 different cancer indications with excellent results. for example the IOERT Breast Boost has shown unparallel results in clinical studies for treating breast cancer with less than 1% recurrence in 10 years. The Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

IntraOp Medical Corporation 570 Del Rey Ave Sunnyvale, CA 94085

Contact: IntraOp Medical Corporation

John Powers, 408-636-1020 ext. 128 email: jpowers@intraopmedical.com

“There is an increasing interest by German hospitals to acquire IOERT capability”, says Ernesto G. Lanzotti, Director of MD51 Germany GmbH, IntraOp Medical European distributor. “The clinical data showing the effectiveness of IOERT for breast cancer compared to the conventional treatment for breast cancer is very convincing, and German hospitals are all looking to provide their patients the best breast cancer treatment possible—and that is IOERT.”

Marien Hospital Düsseldorf GmbH in the city of Dusseldorf, is one of the most important treatment centers in North Rhine-Westphalia (NRW), very famous for its Breast Cancer unit. Doctor Martin Meyer, CEO of Marien Hospital, says “the acquisition of the Mobetron will help increase the standard of care in our Hospital and will allow Professor Audretsch to implement and increase the positive results we are achieving in the cure of Breast Cancer. Mobetron is for us a strategic investment for the future and for the development of our Hospital”.

Professor Werner Audretsch, one of the most famous breast surgeons in Europe, stated that “the Mobetron will help us to shorten the treatment time, to raise the bar of quality in Oncoplastic Surgery and allow us to obtain better results in terms of cosmesis, quality of surgery, increase of success against breast cancer and of course, and most important, will bring to our patients a brighter view and hope of their future.”

Professor Dr. med. Karl Axel Hartmann, radiation oncologist, adds that “the start of our IOERT program with the Mobetron will be a big boost both for our Institution and the standard of care for breast cancer in our region. I am sure that the collaegues of our surgery department will develop other treatment options to be added to the breast cancer programme. The Mobetron is a true linear accelerator which will make it easy to expand our IOERT program to other cancer sites in the future.”

“We are very excited to add Marien Hospital to growing list of world class cancer centers using the Mobetron. IOERT for breast cancer is becoming very prevalent throughout Europe.” said John Powers, President and CEO of IntraOp Medical. The Mobetron uses electron radiation, IOERT, which is the fastest, safest, most versatile, and precise way to deliver radiation therapy. The Mobetron delivers concentrated electron beam radiation directly to the exposed tumor bed to an exact depth during cancer surgery.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms or office settings and has been used to treat over 20 different cancer indications. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program. For more information email jpowers@intraopmedical.com or call 408-636-1020 x128.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Sunnyvale, California; February 13, 2008 – IntraOp Medical Corporation (OTCBB: IOPM), announced today that two North American hospitals that use the Mobetron as part of their cancer treatment protocol will welcome doctors from the Cancer Institute & Hospital, Chinese Academy of Medical Sciences (CAMS), for a scholarly exchange on intraoperative electron-beam radiation therapy (IOERT). Radiation and surgical oncologists from The Ohio State University and The University of North Carolina at Chapel Hill will embark on a long-term commitment to international education and research collaboration by sharing their facilities with their peers from CAMS for two weeks beginning on February 15, 2008.
The premier cancer research and treatment center in China, CAMS conducts more than 10,000 cancer operations each year. In one month, CAMS doctors perform more than 900 cancer surgeries. This is equivalent to the annual volume of cancer surgeries of many U.S. hospitals. CAMS installed IntraOp’s Mobetron in the fall of 2007, and in doing so became the first hospital in China to offer operating room-based IOERT. While the Mobetron is currently being used by CAMS to treat China’s growing number of lung cancer cases, the facility’s doctors are also eager to learn how fellow surgeons and radiologists are using the Mobetron to fight other disease types, including colorectal, head and neck cancer, pancreatic cancer and breast cancer.
In order to facilitate this learning process, Don Goer, IntraOp founder and chief scientist, along with Dr. John C. Grecula, M.D., a radiation oncologist at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State, traveled to Beijing to conduct a week-long IOERT symposium for more than 150 cancer specialists at CAMS in October, 2007. Dr. Grecula presented on practical topics, such as room and patient set-up, as well as IOERT treatment options for advanced head and neck and colorectal cancers.
This symposium marked the beginning of IntraOp’s commitment to bringing cutting-edge cancer centers together to continue the IOERT learning process. The CAMS doctors arrive in the United States on February 14 and will visit four hospitals that currently use the Mobetron as part of their cancer-fighting regimen.
The CAMS practitioners participating in this scholarly exchange include Dr. Tiecheng Wu, thoracic surgeon and associate professor; Dr. Qi Xue, general surgeon and associate professor; Dr. Jun Zhang, thoracic surgeon and associate professor; Dr. Minghui Li, radiation oncologist; Dr. Xiuhong Wu, medical physicist; and Jun Zhao, chief operating room nurse. On February 15, the CAMS scholars will visit The University of California at San Francisco, home of the first Mobetron, to share their experiences with the doctors on staff. They will discuss best practices for using the Mobetron, as well as how IOERT can be used to treat many types of cancer. The CAMS group will reunite with Dr. Grecula at the James Cancer Hospital and Solove Research Institute at Ohio State for additional instruction on February 17 and will complete their trip with a visit to UNC to meet and collaborate with Dr. Benjamin Calvo, associate professor and chief of the division of surgical oncology. In addition to the above centers, St. Vincent’s Hospital of Indianapolis intends to support this training effort.
“I am delighted to welcome the CAMS doctors and their staff to the United States as part of our ongoing collaboration on IOERT treatment techniques,” said Dr. Grecula. “CAMS is the most prestigious cancer research and treatment center in China. At the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, we share CAMS’ unwavering commitment to finding inventive new ways to eradicate even the most late-stage cancers.”
“The Lineberger Comprehensive Cancer Center of the University of North Carolina Chapel Hill has utilized IOERT to treat patients afflicted with breast, colorectal and soft tissue tumors for the past 7 years,” said Dr. Ben Calvo, associate professor and chief divison of surgical oncology at the University of North Carolina. “The NIH funded Breast and GI S.P.O.R.E. (Special Projects of Research Excellence) grants held by our center permit significant translational science to study radiation responses of these tumors. It is our intent to develop strong clinical and basic science collaborations with our distinguished colleagues from CAMS.”
“IntraOp has taken the lead in uniting the leading minds of IOERT,” said Dr. Jie He, vice-dean and professor and chairman of thoracic surgery, CAMS. “We think the Mobetron and IOERT will form an integral part of our cancer program, and we thank IntraOp and all of the facilities involved in the scholarly exchange for giving us the opportunity to come together and learn from one another’s IOERT techniques.”
Dr. Peter Yu, IntraOp’s director of Far East operations, added, “CAMS sets the standard in China for cutting-edge cancer research and treatment. Doctors from regional cancer centers in China’s 30 provinces who will acquire Mobetrons in the future will travel to CAMS to learn the latest IOERT treatment options and techniques. In this regard, CAMS’ Mobetron will play a vital role in IOERT training not only for CAMS physicians, but also for the hundreds of surgical and radiation oncologists who train at CAMS and then return to their own hospitals across China.

About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com.

Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Sunnyvale, California; November 25, 2008 — IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, announced today that it has received an order for the Mobetron from Azienda Ospedaliero-Universitaria “Ospedali Riuniti” Trieste in Northern Italy.

IntraOp’s Mobetron is a mobile device that delivers intraoperative electron-beam radiation therapy (IOERT) to a tumor site during cancer surgery. The Mobetron enables radiation and surgical oncologists to target the exact area that requires radiation and to deliver an effective dose of radiation directly to the affected tissue during surgery. Since the Mobetron is a mobile, self-shielded device, doctors will be able to move the Mobetron between operating rooms, avoiding the high cost of outfitting radiation rooms to accommodate traditional linear accelerators. Ospedali Riuniti will use the Mobetron to treat many forms of cancer but have acquired the device to specifically expand their treatment for breast cancer.

The radiotherapy facility at Ospedali Riuniti has been treating patients for over 40 years and has been a leader in implementing new technology for the treatment of cancer. As part of the oncology department, the radiotherapy department currently treats 1000 patients per year, and includes the Radiotherapy Comprehensive Division (Struttura Complessa di Radioterapia). This division deals with all aspects of care for cancer patients, ranging from treatment to medical advice.

Ospedali Riuniti will join a regional program with Centro di Riferimento Oncologico (CRO) in Aviano Italy, in an effort to provide the best cancer treatment possible to the region. CRO adopted the Mobetron in 2007 and is one of the few hospitals in Italy that has been given the status of Institute for Research in the Cure of Cancer and Scientific Study (“IRCSS” – Istituto per la Ricerca e la Cura del Cancro a Carattere Scientifico). Working with CRO will propel Ospedali Riuniti to be a leader in advanced cancer treatments. It will also give patients in the area an opportunity to take advantage of an innovative treatment that can significantly cut down on treatment time and side effects.

Chief Radiology Oncologist Dr. Aulo Beorchia played a key role in helping to bring IOERT and the Mobetron to the facility, and has been a pioneer in bringing the hospital to the forefront of cancer treatment. “We are truly excited to be joining CRO in providing IOERT to our cancer patients,” Beorchia said. “Working together, both parties will be able to expand research studies and give more patients the opportunity to receive the best treatment available. This is about quality of care, quality of life and curing the disease.”

“Dr. Beorchia and Ospedali Riuniti are passionate and dedicated to the fight against cancer,” said John Powers, CEO of IntraOp Medical. “We are glad to see Italy at the forefront of IOERT adaption and helping them to reach many new patients. Ospedali Riuniti has plans to participate with other Mobetron facilities in the Northern Region of Italy in joint trials on advance cancers that are especially well served by the Mobetron.”

About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
For more information about IntraOp Medical and the Mobetron, please visit: www.intraopmedical.com

For more information about Azienda Ospedaliero-Universitaria “Ospedali Riuniti” Trieste, please visit: www.aots.sanita.fvg.it/aots/portale/welcome.asp?lang=2

Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

UCSF Medical Center ranks among the nation’s top 10 premier hospitals for the tenth consecutive year according to the 2010-11 America’s Best Hospitals survey conducted by U.S. News & World Report. UCSF is a recognized innovator in cancer treatment, and home of the world’s first Mobetron. The Mobetron has been used to integrate IOERT into cancer treatment programs since December 1997. The Mobetron at UCSF has been treated hundreds of advanced and recurrent cancers, such as recurrent head and neck cancer, mesothelioma, recurrent rectal cancer, neuroblastoma, extremity and retroperitoneal sarcomas, and pediatric cancers.
“UCSF is committed to providing state-of-the-art, quality care to patients. IOERT focuses
radiation directly where it is needed and avoids irradiating much of the healthy tissues. We look forward to making this therapy available to even more of our adult and pediatric cancer patients,” said Mack Roach, MD, chair of the UCSF Radiation Oncology Department.

IntraOp’s Mobetron is a mobile, self-shielded, technology that delivers radiation directly to a tumor site during cancer surgery without having to pass through the surrounding body structures. This procedure is called IOERT. The Mobetron enables radiation and surgical professionals to visually pinpoint the optimal site for radiation by seeing the exposed tumor bed and delivering a concentrated beam of radiation to a specific depth during cancer surgery. Clinical studies involving a number of cancer indications such as head and neck, sarcomas, colorectal, pancreatic, and breast, have shown that patients treated with IOERT often have fewer recurrences, which correlates to increased survival.

This purchase represents the 15th and 16th Mobetrons in the United States, and the 36th and 37th, worldwide. John Powers, CEO of IntraOp commented, “It is only fitting that our first customer be one of the first to have our next generation machine along with Avera McKennan Hospital, and The Cleveland Clinic. I am pleased to see Mobetron delivered IOERT grow in popularity worldwide.”

About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intra-operative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielded intra-operative electron radiation therapy device designed for use in any operating room or office setting. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

University of California Disclaimer Statement

The information stated above was prepared by IntraOp Medical Corporation and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of IntraOp Medical Corporation, or any of its products, by The Regents of the University of California, its officers, agents and employees.

What every woman should know about intraoperative radiation
It seems a matter of common sense. Lumpectomy is typically followed by a six-week course of radiation therapy to help eliminate any remaining malignant cells. Treatment takes place at least four weeks after surgery when the breast has healed. Because traditional, post-operative radiation is delivered externally, it must pass through the body to reach diseased areas, and healthy tissue may be damaged in the process. Additionally, once surgery is complete, physicians no longer have direct access to the target area to easily and precisely deliver radiation.
So why not begin the radiation treatment during the surgery itself? This would immediately target any remaining cancer cells, while allowing complete access to the tumor area for greater precision in radiation delivery. It also would spare radiation dose to surrounding tissue and reduce the number of days a woman has to travel to a cancer center for external treatment after surgery. In fact, at St. Joseph, IOERT will shorten the course of post-operative radiation by seven to 10 days by delivering the targeted boost dose prior to, rather than after, traditional treatments.
“The answer is that intraoperative radiation simply hasn’t been practical until now,” explains John Powers, CEO for IntraOp. ”Without the Mobetron, the treatment would mean equipping a special operating room with a costly, unwieldy 18,000 pound linear accelerator to generate radiation as well as a shielded radiation vault to protect staff from repeated exposure to this radiation. This is just not feasible for most hospitals.”
The other alternative, Mr. Powers points out, has been transferring patients under anesthesia with an open incision from the OR to a radiation therapy center, typically located offsite. This significantly increases the risk and duration of surgery and anesthesia. The result: despite its enormous benefits, IOERT has rarely been used in the US for breast patients.
However, IORT has been heavily investigated in major European university hospitals and is currently in use in more than a dozen facilities. This is not surprising because historically the European medical system has been an early adopter of promising new paradigms for breast cancer diagnosis and treatment, including mammography, breast conserving lumpectomy and sentinel node biopsy.

The Mobetron
Specifically optimized for IOERT, the IntraOp Mobetron incorporates a range of technological innovations to make all the benefits of this treatment realistic and practical for women and their doctors around the world. The innovative system eliminates the risk, time, cost and complexity of IOERT by enabling delivery in any standard OR.
Unlike conventional linear accelerators, the Mobetron is relatively lightweight and can be wheeled among different OR locations. The Mobetron requires no external radiation vault or bunker because patented technologies eliminate most stray room radiation generated by conventional accelerators and because of its patented self-shielding,
To operate the device, following tumor excision, a Mobetron applicator tube is temporarily inserted into the breast to provide precise treatment directly to the tumor bed. The Mobetron is positioned for radiation delivery, and the one-minute treatment takes place.

About InterOp Medical Corporation
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, immediate palliative effect, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics world-wide are increasingly using the Mobetron to treat a wide variety of cancers as a vital part of their comprehensive cancer program.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in any operating room or office setting. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.